Natco enters agreement to acquire Dash Pharmaceuticals
The acquisition of Dash Pharmaceuticals will provide additional opportunities in the United States, the company said.
Natco Pharma announced that through its affiliates it is proposing to enter into an agreement to acquire Dash Pharmaceuticals subject to satisfactory completion of due diligence, execution of definitive agreements and compliance with statutory requirements.
[Read more: Natco receives FDA nod for 2 generics]
Dash is a front-end pharmaceutical sales, marketing and distribution entity based in New Jersey, which is expected to have approximate net sales of $15 million for the year ending December 2021.
Natco shared that this acquisition will provide Natco with a "front-end to engage with its customers directly in the United States."
[Read more: Natco, Breckenridge obtain FDA nod for generic Kyprolis]